PE20050588A1 - Composicion para liberacion sostenida que comprende pitavastatina - Google Patents
Composicion para liberacion sostenida que comprende pitavastatinaInfo
- Publication number
- PE20050588A1 PE20050588A1 PE2004001169A PE2004001169A PE20050588A1 PE 20050588 A1 PE20050588 A1 PE 20050588A1 PE 2004001169 A PE2004001169 A PE 2004001169A PE 2004001169 A PE2004001169 A PE 2004001169A PE 20050588 A1 PE20050588 A1 PE 20050588A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- amount
- pitavastatin
- internal
- polyethylene glycol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 title abstract 4
- 229960002797 pitavastatin Drugs 0.000 title abstract 4
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 239000002702 enteric coating Substances 0.000 abstract 2
- 238000009505 enteric coating Methods 0.000 abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 239000000454 talc Substances 0.000 abstract 2
- 229910052623 talc Inorganic materials 0.000 abstract 2
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000004408 titanium dioxide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52537303P | 2003-11-26 | 2003-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050588A1 true PE20050588A1 (es) | 2005-09-05 |
Family
ID=34632977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004001169A PE20050588A1 (es) | 2003-11-26 | 2004-11-26 | Composicion para liberacion sostenida que comprende pitavastatina |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070218134A1 (https=) |
| EP (1) | EP1689398A2 (https=) |
| JP (1) | JP2007512287A (https=) |
| KR (1) | KR20060118507A (https=) |
| CN (1) | CN1905880A (https=) |
| AR (1) | AR046458A1 (https=) |
| AU (1) | AU2004292768B2 (https=) |
| BR (1) | BRPI0417011A (https=) |
| CA (1) | CA2546244A1 (https=) |
| MX (1) | MXPA06005953A (https=) |
| MY (1) | MY147202A (https=) |
| PE (1) | PE20050588A1 (https=) |
| RU (1) | RU2006122630A (https=) |
| TW (1) | TW200534876A (https=) |
| WO (1) | WO2005051346A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048413B2 (en) * | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
| CN102048701B (zh) * | 2010-11-29 | 2013-01-09 | 青岛黄海制药有限责任公司 | 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法 |
| US9399064B2 (en) * | 2011-04-12 | 2016-07-26 | Sawai Pharmaceutical Co., Ltd. | Pitavastatin-containing preparation and method for producing same |
| WO2012153181A1 (en) * | 2011-05-11 | 2012-11-15 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts |
| WO2014129568A1 (ja) | 2013-02-22 | 2014-08-28 | ゼリア新薬工業株式会社 | 腸溶錠 |
| KR102425303B1 (ko) * | 2014-08-13 | 2022-07-25 | 세다르스-신나이 메디칼 센터 | 항-메탄생성 조성물 및 그것의 용도 |
| WO2016161085A1 (en) | 2015-04-01 | 2016-10-06 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
| IL319156A (en) * | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
| CN111053752A (zh) * | 2018-10-16 | 2020-04-24 | 南京卓康医药科技有限公司 | 一种稳定的匹伐他汀钙的肠溶片及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5032406A (en) * | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
| US5916595A (en) * | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
| CN1440283A (zh) * | 2000-04-12 | 2003-09-03 | 诺瓦提斯公司 | 有机化合物的联合形式 |
| CA2359812C (en) * | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
| AU2002324715B2 (en) * | 2001-08-16 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Processes for preparing calcium salt forms of statins |
| TW200404544A (en) * | 2002-06-17 | 2004-04-01 | Kowa Co | Controlled release pharmaceutical composition |
| GB0217306D0 (en) * | 2002-07-25 | 2002-09-04 | Novartis Ag | Compositions comprising organic compounds |
| SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
-
2004
- 2004-11-24 MY MYPI20044867A patent/MY147202A/en unknown
- 2004-11-25 AU AU2004292768A patent/AU2004292768B2/en not_active Ceased
- 2004-11-25 CA CA002546244A patent/CA2546244A1/en not_active Abandoned
- 2004-11-25 RU RU2006122630/15A patent/RU2006122630A/ru not_active Application Discontinuation
- 2004-11-25 KR KR1020067010228A patent/KR20060118507A/ko not_active Withdrawn
- 2004-11-25 TW TW093136328A patent/TW200534876A/zh unknown
- 2004-11-25 MX MXPA06005953A patent/MXPA06005953A/es active IP Right Grant
- 2004-11-25 US US10/580,895 patent/US20070218134A1/en not_active Abandoned
- 2004-11-25 CN CNA2004800409427A patent/CN1905880A/zh active Pending
- 2004-11-25 JP JP2006540391A patent/JP2007512287A/ja active Pending
- 2004-11-25 BR BRPI0417011-3A patent/BRPI0417011A/pt not_active IP Right Cessation
- 2004-11-25 AR ARP040104363A patent/AR046458A1/es not_active Application Discontinuation
- 2004-11-25 EP EP04819224A patent/EP1689398A2/en not_active Withdrawn
- 2004-11-25 WO PCT/EP2004/013419 patent/WO2005051346A2/en not_active Ceased
- 2004-11-26 PE PE2004001169A patent/PE20050588A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1689398A2 (en) | 2006-08-16 |
| AU2004292768B2 (en) | 2009-04-02 |
| MY147202A (en) | 2012-11-14 |
| AR046458A1 (es) | 2005-12-07 |
| RU2006122630A (ru) | 2008-01-10 |
| CN1905880A (zh) | 2007-01-31 |
| TW200534876A (en) | 2005-11-01 |
| WO2005051346A3 (en) | 2005-08-25 |
| JP2007512287A (ja) | 2007-05-17 |
| KR20060118507A (ko) | 2006-11-23 |
| US20070218134A1 (en) | 2007-09-20 |
| MXPA06005953A (es) | 2006-07-06 |
| AU2004292768A1 (en) | 2005-06-09 |
| BRPI0417011A (pt) | 2007-02-21 |
| WO2005051346A2 (en) | 2005-06-09 |
| CA2546244A1 (en) | 2005-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050552A1 (es) | Composicion farmaceutica compuesta por acido nicotinico u otro agonista del receptor de acido nicotinico y un antagonista del receptor dp | |
| ES2543007T3 (es) | Micropartículas que comprenden sales de dicetopiperazina para la administración de fármacos | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| HRP20200379T1 (hr) | Spojevi pirimidindiona protiv srčanih stanja | |
| PE20050588A1 (es) | Composicion para liberacion sostenida que comprende pitavastatina | |
| CO2021007447A2 (es) | Métodos de tratamiento para la fibrosis quística | |
| EP2589379A4 (en) | TRANSDERMAL AGGREGATE FREEZING SYSTEM WITH DONEPEZIL | |
| UA103844C2 (ru) | Фармацевтический состав, который содержит в матрице, которая подвергается эрозии, один или более эфиров фумаровой кислоты | |
| AR088875A1 (es) | Forma de dosis farmaceutica oral a prueba de manipulacion | |
| FI3154594T3 (fi) | Fap-aktivoituja terapeuttisia aineita ja niihin liittyviä käyttöjä | |
| AR067184A1 (es) | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica | |
| EP1894567A4 (en) | Concomitant pharmaceutical agents and use thereof | |
| HRP20250776T1 (hr) | Elafibranor za uporabu u liječenju primarnog bilijarnog kolangitisa | |
| UY27532A1 (es) | Forma de dosificación de liberación controlada dual. | |
| ATE554778T1 (de) | Verfahren, pharmazeutische zusammensetzungen und hergestellte artikel zur verabreichung von therapeutischen zellen an das zentrale nervensystem eines tiers | |
| BR0115965A (pt) | Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos | |
| AR065120A1 (es) | Compuesto de aril pirazol azoespirodecanona, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende | |
| MX2018008021A (es) | Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones. | |
| PE20110432A1 (es) | Etexilato de dabigatran o una sal del mismo | |
| AR085173A1 (es) | Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas | |
| AR062453A1 (es) | Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia | |
| CO6270217A2 (es) | Formulaciones galenicas de alisquireno y valsartan | |
| BRPI0412458A (pt) | composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada | |
| MX2009003360A (es) | Formulaciones orales liofilizadas de desintegracion rapida de un antagonista del receptor de trombina. | |
| AR089765A1 (es) | Un sistema para el suministro de un farmaco |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |